Nesiritide in Hypertension

Summary

Nesiritide in Hypertension is a clinical trial^[1].

Key Facts

• Nesiritide in Hypertension is in the country of Norway^[2].
• Nesiritide in Hypertension's instance of is recorded as clinical trial^[3].
• Nesiritide in Hypertension's start time is recorded as +2015-12-31T00:00:00Z^[4].
• Nesiritide in Hypertension's end time is recorded as +2018-12-31T00:00:00Z^[5].
• Nesiritide in Hypertension's contributor to the creative work or subject is recorded as University of Oslo^[6].
• Nesiritide in Hypertension's sponsor is recorded as Oslo University Hospital^[7].
• Nesiritide in Hypertension's main subject is recorded as arterial hypertension^[8].
• Nesiritide in Hypertension's number of participants is recorded as {'unit': '1', 'amount': '+15'}^[9].
• Nesiritide in Hypertension's title is recorded as Therapeutic Effects of BNP in Hypertensive Patients^[10].
• Nesiritide in Hypertension's short name is recorded as TENSE1^[11].
• Nesiritide in Hypertension's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[12].
• Nesiritide in Hypertension's ClinicalTrials.gov ID is recorded as NCT02608996^[13].
• Nesiritide in Hypertension's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+79'}^[14].
• Nesiritide in Hypertension's clinical trial phase is recorded as phase I clinical trial^[15].
• Nesiritide in Hypertension's clinical trial phase is recorded as phase II clinical trial^[16].
• Nesiritide in Hypertension's study type is recorded as interventional study^[17].